Clinical trial

Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)

NCT07486089

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

BIOLOGICAL · Unmapped registry intervention Dual-target CAR-NK cells (EB-DT-CAR-NK) Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Lymphodepleting chemotherapy Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention Supportive care Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE1, PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2026-02-02

PhasePHASE1 / PHASE2

Conditions

Breast Cancer (Locally Advanced or Metastatic)unresolved

HER2-positive Breast Cancerunresolved

Triple-Negative Breast Cancer (TNBC)unresolved

Interventions

Dual-target CAR-NK cells (EB-DT-CAR-NK)BIOLOGICAL

Lymphodepleting chemotherapyDRUG

Supportive careOTHER

Sponsors & collaborators

Beijing Biotechlead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07486089 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.